Low IDL causes

Jump to: navigation, search

Intermediate Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Biochemistry

Physiology

Clinical Correlation

High IDL

Epidemiology and Demographics
Pathophysiology
Causes
Diseases
Prognosis and Complications

Low IDL

Epidemiology and Demographics
Pathophysiology
Causes
Diseases
Prognosis and Complications

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Landmark Trials

Future or Investigational Therapies

Case Studies

Case #1

Low IDL causes On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Low IDL causes

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Low IDL causes

CDC on Low IDL causes

Low IDL causes in the news

Blogs on Low IDL causes

Directions to Hospitals Treating Intermediate density lipoprotein

Risk calculators and risk factors for Low IDL causes

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ogheneochuko Ajari, MB.BS, MS [2]

Overview

IDL, formed from the degradation of VLDL, transports a variety of triglyceride fats and cholesterol. Disorders that cause a decrease in IDL (or low IDL) are few and are limited to an enzyme deficiency or genetic causes and medication side effects.

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.

There are no life threatening causes of low IDL.

Common Causes

Causes by Organ System

Cardiovascular No underlying causes
Chemical/Poisoning No underlying causes
Dental No underlying causes
Dermatologic No underlying causes
Drug Side Effect Estrogen plus simvastatin combination therapy, extended-release niacin/laropiprant and simvastatin, lovastatin, pravastatin, statins
Ear Nose Throat No underlying causes
Endocrine No underlying causes
Environmental No underlying causes
Gastroenterologic Lipoprotein lipase deficiency
Genetic Familial apolipoprotein AI and apolipoprotein CIII deficiency, lipoprotein lipase deficiency
Hematologic No underlying causes
Iatrogenic No underlying causes
Infectious Disease No underlying causes
Musculoskeletal/Orthopedic No underlying causes
Neurologic No underlying causes
Nutritional/Metabolic No underlying causes
Obstetric/Gynecologic No underlying causes
Oncologic No underlying causes
Ophthalmologic No underlying causes
Overdose/Toxicity No underlying causes
Psychiatric No underlying causes
Pulmonary No underlying causes
Renal/Electrolyte No underlying causes
Rheumatology/Immunology/Allergy No underlying causes
Sexual No underlying causes
Trauma No underlying causes
Urologic No underlying causes
Miscellaneous No underlying causes

Causes in Alphabetical Order

References

  1. Wakatsuki A, Okatani Y, Ikenoue N (2000). "Effects of combination therapy with estrogen plus simvastatin on lipoprotein metabolism in postmenopausal women with type IIa hypercholesterolemia". Atherosclerosis. 150 (1): 103–11. PMID 10781640.
  2. Ballantyne C, Gleim G, Liu N, Sisk CM, Johnson-Levonas AO, Mitchel Y (2012). "Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia". J Clin Lipidol. 6 (3): 235–43. doi:10.1016/j.jacl.2011.11.004. PMID 22658147.
  3. Forte TM, Nichols AV, Krauss RM, Norum RA (1984). "Familial apolipoprotein AI and apolipoprotein CIII deficiency. Subclass distribution, composition, and morphology of lipoproteins in a disorder associated with premature atherosclerosis". J Clin Invest. 74 (5): 1601–13. doi:10.1172/JCI111576. PMC 425337. PMID 6501564.
  4. Mack WJ, Krauss RM, Hodis HN (1996). "Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression". Arterioscler Thromb Vasc Biol. 16 (5): 697–704. PMID 8963728.
  5. Nishizawa Y, Shoji T, Tabata T, Inoue T, Morii H (1999). "Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients". Kidney Int Suppl. 71: S134–6. PMID 10412757.
  6. Lee SJ, Sacks FM (2003). "Effect of pravastatin on intermediate-density and low-density lipoproteins containing apolipoprotein CIII in patients with diabetes mellitus". Am J Cardiol. 92 (2): 121–4. PMID 12860210.



Linked-in.jpg